Developer docs
API playgroundTry for free, no card

Search company profiles

C the Signs

Full company profile

uuid0000m9d

Namestring
C the Signs
Legal namestring
C the Signs Limited
Websiteurl
cthesigns.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

C the Signs is a London-based, privately-held clinical AI company founded in 2017 by NHS doctors Dr. Bea Bakshi (CEO) and Dr. Miles Payling (CSO) to address late cancer detection in primary care. The company's core product is a clinical decision support platform that analyzes patient symptoms, risk factors, demographics, and electronic medical record data against more than 1,000 validated evidence-based data points to identify individuals at risk of cancer across 100+ cancer types in under 60 seconds. The platform is UKCA-marked, MHRA-regulated, and accredited under NHS Clinical Safety standards DCB0129/0160, and integrates natively into the three principal UK GP electronic medical record systems: EMIS Web (used by ~70% of English GP practices), SystmOne, and Vision. A complementary patient-facing product, the C my Signs Self-Assessment Service, enables direct self-referral pathways without a GP visit, with endometrial cancer live since August 2024 and colorectal and lung cancer pathways planned.

The company's technology is clinically validated across more than 500,000 patient records, achieving 99% sensitivity for cancer detection and 94% accuracy in predicting tumor site of origin, and is deployed in 1,500+ UK GP practices covering more than 10 million patient lives. To date, 70,000+ patients with cancer have been detected through the platform, with a cancer detection rate of 66% reported across deployments, up from 58.7% baseline. C the Signs is commissioned primarily through NHS Integrated Care Boards, Primary Care Networks, Cancer Alliances, and NHS England programmes, with services provided free of charge to individual clinicians. Strategic partnerships with Health Innovation East, Health Innovation Wessex, Somerset NHS Foundation Trust, East Midlands Cancer Alliance, and the Mayo Clinic (for research validation) anchor the go-to-market. The company has raised a £5 million seed round in February 2022 and an $8 million Series A led by Khosla Ventures in January 2025, primarily to fund expansion from the UK into the United States.

Short descriptiontext

C the Signs is a London-based AI company that provides a clinical decision support platform for early cancer detection in primary care, integrated into NHS GP electronic medical record systems and deployed across 1,500+ UK practices covering 10M+ patient lives.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cancer detection, clinical decision support, primary care software, cancer risk assessment, medical device software
Industry2 codes
PRIMARYHLACAGAE
Risk Stratification, Early Warning Scores & Predictive Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAEAF
Patient Intake, Digital Registration & eForms
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
NAICS code1 code
  • Computer Systems Design Services541512
SIC code1 code
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Clinical Decision Support Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1NHS Commissioning Contracts
TypeSubscription Recurring
Description

C the Signs is commissioned by NHS-funded bodies including GP practices, Primary Care Networks, Integrated Care Boards, Cancer Alliances, and NHS England. Services are provided free to individual healthcare practitioners while payment comes from NHS commissioning bodies.

cthesigns.com
2Health Innovation Partnerships
TypeSubscription Recurring
Description

Partnerships with Health Innovation East and Health Innovation Wessex support regional expansion and commissioning of the platform across NHS Integrated Care Systems.

cthesigns.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details1 tier
1Free for individual healthcare practitioners
ModelFreemiumBilling cadenceAnnual
Notes

Individual healthcare professionals can access C the Signs services free of charge, with NHS commissioning bodies covering the cost.

cthesigns.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

C the Signs is an AI-powered clinical decision support platform that analyzes patient symptoms, demographics, risk factors, and electronic medical record data across 1,000+ validated evidence-based data points to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with NHS GP systems (EMIS, SystmOne, Vision) and is complemented by a patient-facing self-assessment service enabling direct triage into diagnostic pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 66% cancer detection rate (up from 58.7%), representing a 12% relative increase in detection
+7 more records
Product overview1 text field

C the Signs offers an AI-powered clinical platform for early cancer detection, consisting of two integrated products: (1) The C the Signs Clinical Decision Support Platform — a core clinical decision support system used by GPs that analyzes patient symptoms, demographics, risk factors, and electronic medical records to identify cancer risk across 100+ cancer types in under 60 seconds, integrating directly with EMIS Web, SystmOne, and Vision GP systems; and (2) The C my Signs Self-Assessment Service — a patient-facing self-referral pathway that enables individuals to complete AI-driven symptom assessments directly (without GP referral), currently deployed for endometrial cancer with plans for colorectal and lung cancer pathways. Both products share the same underlying AI algorithms and evidence base, with the Self-Assessment Service representing an extension of the platform to direct patient use.

Product and service2 records
1C the Signs Clinical Decision Support Platform
CategoryClinical Decision Support Software
Description

AI-powered clinical decision support system for GPs and primary care clinicians that analyzes patient symptoms, demographics, risk factors, and electronic medical records to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with EMIS Web, SystmOne, and Vision EMR systems and is used across over 1,500 UK GP practices covering 10+ million patient lives.

2C my Signs Self-Assessment Service
CategoryPatient Self-Assessment Service
Description

Patient-facing AI-driven self-assessment and self-referral pathway that enables individuals to complete an evidence-based cancer risk assessment via the NHS App or website without a GP referral. Currently deployed for endometrial cancer, with patients triaged directly to ultrasound or diagnostic services if cancer risk is indicated.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Health Innovation East
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Health Innovation East commissioned the evaluation of C the Signs across Suffolk and North East Essex ICB, demonstrating 808% ROI. Subsequently supported expansion across Norfolk and Waveney ICB and broader East of England.

cthesigns.com
2East Midlands Cancer Alliance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-19
Description

Partnership with East Midlands Cancer Alliance to deploy C the Signs across every GP practice in Northamptonshire, supporting equitable early cancer diagnosis across the county.

cthesigns.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Pioneering partnership to launch UK's first AI-driven self-referral service for endometrial cancer, enabling women to self-refer for diagnostic ultrasound without GP referral. This model is being expanded to colorectal and lung cancer pathways.

4The Eve Appeal
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-08
Description

Women's cancer charity Ask Eve Nurse Service endorsed the endometrial cancer self-referral service, providing credibility and support for patient awareness.

cthesigns.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

C the Signs deployment through NHS England's Innovation for Healthcare Inequalities Programme (InHIP) designed to reduce variation in access to care and improve outcomes across deprived communities.

6Health Innovation Wessex
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-10
Description

Partnered with Health Innovation Wessex to launch C the Signs across 70 GP practices in Dorset ICS, supporting earlier cancer detection for a population with high cancer rates.

cthesigns.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Research collaboration using Mayo Clinic patient data to validate C the Signs AI models. Multiple peer-reviewed studies published on early detection of lung, breast, prostate, colorectal, and pancreatic cancers.

8EMIS
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-01-01
Description

Deep integration with EMIS Web electronic medical record system, used by approximately 70% of GP practices in England, enabling seamless access to C the Signs cancer risk assessment within existing clinical workflows.

cthesigns.com
9SystmOne (TPP)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-01-01
Description

Integration with SystmOne electronic medical record system supporting thousands of GP practices, community services, and hospitals across the NHS.

cthesigns.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based cancer risk assessment and clinical decision support platform for primary care and OB/GYN practices. Most directly comparable to C the Signs: AI-driven hereditary and familial cancer risk prediction integrated into EHR workflow to support earlier identification and referral.

TypeDirect peer
Description

UK-based AI medical device for skin cancer detection in primary care pathways, deployed through NHS commissioning. Comparable as a UK AI cancer detection CDS validated as a regulated medical device and integrated into NHS GP workflows.

TypeDirect peer
Description

UK-based AI company focused on breast cancer screening (Mia) deployed in NHS and European radiology pathways. Comparable as a UK-headquartered AI cancer detection company operating under MHRA regulations and selling into NHS commissioning structures.

TypeDirect peer
Description

UK-based AI-enabled diagnostic company focused on early cancer detection (esophageal and other GI cancers) through NHS pathways. Comparable as a UK AI cancer detection company building evidence and NHS commissioning traction in early-diagnosis pathways.

TypeDirect peer
Description

AI-driven breast cancer risk assessment and imaging analytics platform used in primary care and screening settings. Comparable as an AI clinical decision support and risk stratification tool for cancer in women's health pathways.

TypeEmerging player
Description

South Korea-based AI company providing cancer detection AI for radiology (mammography, chest x-ray) and pathology. Comparable as a regulated AI cancer detection CDS company expanding globally across healthcare systems.

7Tempus
TypeBroad incumbent
Description

US precision medicine company applying AI to clinical and molecular data for oncology decision support. Comparable in the use of AI to inform oncology clinical decision-making, though broader in scope (molecular profiling, trials) than C the Signs' primary care focus.

TypeBroad incumbent
Description

Health technology incumbent offering oncology-focused clinical decision support and analytics solutions to health systems and payers. Comparable as a broad healthcare AI/analytics incumbent with oncology CDS capabilities competing for health system IT budgets.

TypeEmerging player
Description

US AI pathology company applying machine learning to cancer diagnostics and biomarker discovery. Comparable as an AI company building regulatory-grade cancer detection tools for clinical decision-making, though focused downstream on pathology rather than primary care.

TypeBroad incumbent
Description

Large incumbent with AI healthcare initiatives spanning oncology screening, clinical decision support, and EHR-embedded tools. Comparable as a potential entrant in AI-driven cancer CDS that could leverage search-scale data and integration with major EHR vendors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

C the Signs

Clinical Decision Support Softwarecthesigns.com

C the Signs is a London-based AI company that provides a clinical decision support platform for early cancer detection in primary care, integrated into NHS GP electronic medical record systems and deployed across 1,500+ UK practices covering 10M+ patient lives.

What C the Signs does

C the Signs is a London-based, privately-held clinical AI company founded in 2017 by NHS doctors Dr. Bea Bakshi (CEO) and Dr. Miles Payling (CSO) to address late cancer detection in primary care. The company's core product is a clinical decision support platform that analyzes patient symptoms, risk factors, demographics, and electronic medical record data against more than 1,000 validated evidence-based data points to identify individuals at risk of cancer across 100+ cancer types in under 60 seconds. The platform is UKCA-marked, MHRA-regulated, and accredited under NHS Clinical Safety standards DCB0129/0160, and integrates natively into the three principal UK GP electronic medical record systems: EMIS Web (used by ~70% of English GP practices), SystmOne, and Vision. A complementary patient-facing product, the C my Signs Self-Assessment Service, enables direct self-referral pathways without a GP visit, with endometrial cancer live since August 2024 and colorectal and lung cancer pathways planned.

The company's technology is clinically validated across more than 500,000 patient records, achieving 99% sensitivity for cancer detection and 94% accuracy in predicting tumor site of origin, and is deployed in 1,500+ UK GP practices covering more than 10 million patient lives. To date, 70,000+ patients with cancer have been detected through the platform, with a cancer detection rate of 66% reported across deployments, up from 58.7% baseline. C the Signs is commissioned primarily through NHS Integrated Care Boards, Primary Care Networks, Cancer Alliances, and NHS England programmes, with services provided free of charge to individual clinicians. Strategic partnerships with Health Innovation East, Health Innovation Wessex, Somerset NHS Foundation Trust, East Midlands Cancer Alliance, and the Mayo Clinic (for research validation) anchor the go-to-market. The company has raised a £5 million seed round in February 2022 and an $8 million Series A led by Khosla Ventures in January 2025, primarily to fund expansion from the UK into the United States.

C the Signs firmographics

Firmographics
Name
C the Signs
Legal name
C the Signs Limited
Website
https://cthesigns.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
C the Signs is a London-based AI company that provides a clinical decision support platform for early cancer detection in primary care, integrated into NHS GP electronic medical record systems and deployed across 1,500+ UK practices covering 10M+ patient lives.
Ownership category
akta.pro rank

C the Signs industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Computer Systems Design Services (541512)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLACAGAE
Risk Stratification, Early Warning Scores & Predictive Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAEAF
Patient Intake, Digital Registration & eForms
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms

Keywords

  • AI cancer detection
  • Clinical decision support
  • Primary care software
  • Cancer risk assessment
  • Medical device software

Where C the Signs is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

C the Signs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. NHS Commissioning Contracts: C the Signs is commissioned by NHS-funded bodies including GP practices, Primary Care Networks, Integrated Care Boards, Cancer Alliances, and NHS England. Services are provided free to individual healthcare practitioners while payment comes from NHS commissioning bodies.
  2. Health Innovation Partnerships: Partnerships with Health Innovation East and Health Innovation Wessex support regional expansion and commissioning of the platform across NHS Integrated Care Systems.

Pricing tiers

ModelBillingPrice
FreemiumAnnualFree for individual healthcare practitioners

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

C the Signs product offering

Product offering

Core offering

C the Signs is an AI-powered clinical decision support platform that analyzes patient symptoms, demographics, risk factors, and electronic medical record data across 1,000+ validated evidence-based data points to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with NHS GP systems (EMIS, SystmOne, Vision) and is complemented by a patient-facing self-assessment service enabling direct triage into diagnostic pathways.

Product overview

C the Signs offers an AI-powered clinical platform for early cancer detection, consisting of two integrated products: (1) The C the Signs Clinical Decision Support Platform — a core clinical decision support system used by GPs that analyzes patient symptoms, demographics, risk factors, and electronic medical records to identify cancer risk across 100+ cancer types in under 60 seconds, integrating directly with EMIS Web, SystmOne, and Vision GP systems; and (2) The C my Signs Self-Assessment Service — a patient-facing self-referral pathway that enables individuals to complete AI-driven symptom assessments directly (without GP referral), currently deployed for endometrial cancer with plans for colorectal and lung cancer pathways. Both products share the same underlying AI algorithms and evidence base, with the Self-Assessment Service representing an extension of the platform to direct patient use.

Differentiator

Problem solved

Functional benefit

Products and services

  • C the Signs Clinical Decision Support Platform AI-powered clinical decision support system for GPs and primary care clinicians that analyzes patient symptoms, demographics, risk factors, and electronic medical records to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with EMIS Web, SystmOne, and Vision EMR systems and is used across over 1,500 UK GP practices covering 10+ million patient lives.
  • C my Signs Self-Assessment Service Patient-facing AI-driven self-assessment and self-referral pathway that enables individuals to complete an evidence-based cancer risk assessment via the NHS App or website without a GP referral. Currently deployed for endometrial cancer, with patients triaged directly to ultrasound or diagnostic services if cancer risk is indicated.

Quantifiable outcome

  • 66% cancer detection rate (up from 58.7%), representing a 12% relative increase in detection
  • +7 more outcomes

Companies that use C the Signs

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

C the Signs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature5 records

C the Signs partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

  • Health Innovation EastcoreStrategic or Co-development Partner · 1 January 2025Health Innovation East commissioned the evaluation of C the Signs across Suffolk and North East Essex ICB, demonstrating 808% ROI. Subsequently supported expansion across Norfolk and Waveney ICB and broader East of England.
  • East Midlands Cancer AlliancecoreStrategic or Co-development Partner · 19 December 2024Partnership with East Midlands Cancer Alliance to deploy C the Signs across every GP practice in Northamptonshire, supporting equitable early cancer diagnosis across the county.
  • Somerset NHS Foundation TrustflagshipStrategic or Co-development Partner · 1 August 2024Pioneering partnership to launch UK's first AI-driven self-referral service for endometrial cancer, enabling women to self-refer for diagnostic ultrasound without GP referral. This model is being expanded to colorectal and lung cancer pathways.
  • The Eve AppealminorStrategic or Co-development Partner · 8 April 2024Women's cancer charity Ask Eve Nurse Service endorsed the endometrial cancer self-referral service, providing credibility and support for patient awareness.
  • NHS England InHIP ProgrammecoreStrategic or Co-development Partner · 1 January 2024C the Signs deployment through NHS England's Innovation for Healthcare Inequalities Programme (InHIP) designed to reduce variation in access to care and improve outcomes across deprived communities.
  • Health Innovation WessexcoreStrategic or Co-development Partner · 10 May 2023Partnered with Health Innovation Wessex to launch C the Signs across 70 GP practices in Dorset ICS, supporting earlier cancer detection for a population with high cancer rates.
  • Mayo CliniccoreStrategic or Co-development Partner · 1 January 2023Research collaboration using Mayo Clinic patient data to validate C the Signs AI models. Multiple peer-reviewed studies published on early detection of lung, breast, prostate, colorectal, and pancreatic cancers.
  • EMIScoreTechnology or Integration · 1 January 2019Deep integration with EMIS Web electronic medical record system, used by approximately 70% of GP practices in England, enabling seamless access to C the Signs cancer risk assessment within existing clinical workflows.
  • SystmOne (TPP)coreTechnology or Integration · 1 January 2019Integration with SystmOne electronic medical record system supporting thousands of GP practices, community services, and hospitals across the NHS.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

C the Signs competitors and assessment

Company assessment

Direct peers

  • CancerIQ: US-based cancer risk assessment and clinical decision support platform for primary care and OB/GYN practices. Most directly comparable to C the Signs: AI-driven hereditary and familial cancer risk prediction integrated into EHR workflow to support earlier identification and referral.
  • Skin Analytics: UK-based AI medical device for skin cancer detection in primary care pathways, deployed through NHS commissioning. Comparable as a UK AI cancer detection CDS validated as a regulated medical device and integrated into NHS GP workflows.
  • Kheiron Medical Technologies: UK-based AI company focused on breast cancer screening (Mia) deployed in NHS and European radiology pathways. Comparable as a UK-headquartered AI cancer detection company operating under MHRA regulations and selling into NHS commissioning structures.
  • Cyted: UK-based AI-enabled diagnostic company focused on early cancer detection (esophageal and other GI cancers) through NHS pathways. Comparable as a UK AI cancer detection company building evidence and NHS commissioning traction in early-diagnosis pathways.
  • Volpara Health: AI-driven breast cancer risk assessment and imaging analytics platform used in primary care and screening settings. Comparable as an AI clinical decision support and risk stratification tool for cancer in women's health pathways.

Emerging players

  • Lunit: South Korea-based AI company providing cancer detection AI for radiology (mammography, chest x-ray) and pathology. Comparable as a regulated AI cancer detection CDS company expanding globally across healthcare systems.
  • PathAI: US AI pathology company applying machine learning to cancer diagnostics and biomarker discovery. Comparable as an AI company building regulatory-grade cancer detection tools for clinical decision-making, though focused downstream on pathology rather than primary care.

Broad incumbents

  • Tempus: US precision medicine company applying AI to clinical and molecular data for oncology decision support. Comparable in the use of AI to inform oncology clinical decision-making, though broader in scope (molecular profiling, trials) than C the Signs' primary care focus.
  • Merative (formerly IBM Watson Health): Health technology incumbent offering oncology-focused clinical decision support and analytics solutions to health systems and payers. Comparable as a broad healthcare AI/analytics incumbent with oncology CDS capabilities competing for health system IT budgets.
  • Google Health: Large incumbent with AI healthcare initiatives spanning oncology screening, clinical decision support, and EHR-embedded tools. Comparable as a potential entrant in AI-driven cancer CDS that could leverage search-scale data and integration with major EHR vendors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

C the Signs social profiles

Digital presence

C the Signs compliance and trust

Trust signal

Compliance4 records

C the Signs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

C the Signs leadership team

Management profile

Number of profiles

Profiles3 records

C the Signs funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

C the Signs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C the Signs

What does C the Signs do?

C the Signs is an AI-powered clinical decision support platform that analyzes patient symptoms, demographics, risk factors, and electronic medical record data across 1,000+ validated evidence-based data points to identify patients at risk of cancer across 100+ cancer types in under 60 seconds. The platform integrates directly with NHS GP systems (EMIS, SystmOne, Vision) and is complemented by a patient-facing self-assessment service enabling direct triage into diagnostic pathways.

Is C the Signs a public or private company?

C the Signs is a private company. It is classified as venture growth investor backed and is currently operating.

When was C the Signs founded?

C the Signs was founded in 2017. It employs 51 to 100 people.

Where is C the Signs based?

C the Signs is headquartered in London, United Kingdom, in the Europe region.

How does C the Signs make money?

Two revenue lines are on record. NHS Commissioning Contracts are the primary driver. The others are health Innovation Partnerships.

Who are C the Signs's main competitors?

Direct peers on record are CancerIQ, Skin Analytics, Kheiron Medical Technologies, Cyted and Volpara Health. Emerging players are Lunit and PathAI. Broad incumbents are Tempus, Merative (formerly IBM Watson Health) and Google Health.

Does C the Signs have an API?

No public API is recorded for C the Signs.

What industry is C the Signs in?

C the Signs's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics, with a secondary code of HLACAEAF, Patient Intake, Digital Registration & eForms. Its NAICS code is 541512 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaThis AI Tool Could Spot Cancer Years Before Diagnosis— And The FDA Is Taking A Look - Pfizer (NYSE:PFE)C the Signs, an AI-powered cancer detection tool, is under FDA De Novo review and could become the first approved device of its kind in the U.S., with the company aiming to launch next year. The technology, already used by over 11,000 healthcare professionals in the UK's National Health Service, has helped identify 75,000 cancer patients while reducing diagnostic timelines by 21% and can analyze years of medical history in under 60 seconds. A Mayo Clinic validation study found one in four cancer patients could be identified one to five years before diagnosis using the platform.BloombergBloomberg Businessweek Daily: Early Cancer DetectionBloomberg Businessweek Daily features a segment in which hosts Carol Massar and Tim Stenovec speak with Dr. Bea Bakshi, co-founder and CEO of C the Signs, an early cancer detection platform. The discussion covers the company's use of AI in its weekly women's health segment. No further details on the platform's technology, pricing, or market reach were disclosed.Business InsiderA doctor shares 5 high-fiber food tips to help lower your risk of colon cancer, from snacks to smoothiesDr. Bea Bakshi, a primary care physician and CEO of cancer detection company C the Signs, shares five dietary tips to help increase fiber intake and reduce colorectal cancer risk. The article notes that over 90% of Americans do not meet the recommended 25-34 grams of fiber daily, while colorectal cancer has become the leading cause of cancer deaths in Americans under 50. The tips include adding nuts and seeds, stocking up on beans, switching to whole grains, snacking on berries and apples, and blending a high-fiber superfood smoothie.HIT ConsultantC the Signs Raises $8M to Expand AI-Powered Cancer Detection to the U.S.C the Signs, a UK-based developer of AI-powered cancer detection solutions, has raised $8 million in a funding round led by Khosla Ventures to support its expansion from the United Kingdom to the United States. The company's AI platform analyzes patient electronic health records to assess individual cancer risk, aiming to identify tumors at earlier, more treatable stages. In the UK NHS, C the Signs has demonstrated results including detecting 20.7% of breast cancer cases up to five years earlier than standard pathways and improving early-stage ovarian cancer diagnosis by 53.3%.Business Wire BlogC the Signs Announces Investment From Khosla Ventures to Advance AI-Powered Early Cancer DetectionC the Signs announced $8 million in funding from Khosla Ventures to expand its AI-based cancer detection platform from the UK to the US. The company's model identified 20.7% of breast cancers up to five years earlier and ovarian cancers 53.3% earlier than standard methods. The capital will accelerate US expansion.The GuardianGPs use AI to boost cancer detection rates in England by 8%An AI tool called C the Signs, used in about 1,400 GP practices in England, raised cancer detection rates from 58.7% to 66.0% by March 2022. The system analyzes patient records and prompts symptom checks, detecting over 50 cancer types. NHS England's long-term plan aims for 75% of cancers diagnosed at early stages by 2028.PR NewswireBritish Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer DeathsC the Signs, a British AI cancer detection company founded by NHS doctors, has been selected as the only British company among 16 firms to join the inaugural cohort of the White House-backed CancerX Accelerator programme. The programme, launched to support the Cancer Moonshot initiative targeting a 50% reduction in cancer mortality over 25 years, provides selected startups opportunities to collaborate with leading cancer and technology organizations. C the Signs' AI platform has detected over 25,000 cancer patients with 98% accuracy and will now collaborate with CancerX Champions including AstraZeneca, Intel, Dell Technologies, and AWS.BusinessCloud£5m for AI cancer detection platform C the SignsC the Signs has raised £5 million in investment from MMC, Ataraxia, and Acequia Capital to scale its AI-powered early cancer detection technology. The company aims to deploy its system in every GP practice in the UK by the end of 2022 to improve patient survival rates through faster diagnosis.